US equities
|
SPCX
$166.74
▲+4.90%
NVDA
$236.75
▲+1.20%
MU
$1,063.10
▼-1.10%
TSLA
$376.85
▲+1.69%
MSFT
$524.10
▲+1.27%
SNDK
$1,704.56
▼-0.90%
INTC
$117.38
▼-1.63%
META
$742.43
▲+1.97%
SPCX
$166.74
▲+4.90%
NVDA
$236.75
▲+1.20%
MU
$1,063.10
▼-1.10%
TSLA
$376.85
▲+1.69%
MSFT
$524.10
▲+1.27%
SNDK
$1,704.56
▼-0.90%
INTC
$117.38
▼-1.63%
META
$742.43
▲+1.97%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Apellis Pharmaceuticals, Inc. - Common Stock
(NQ:
APLS
)
41.03
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 09, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
What Analysts Are Saying About Apellis Pharmaceuticals Stock
↗
June 28, 2024
Via
Benzinga
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
June 28, 2024
Via
Benzinga
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
June 28, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
↗
May 28, 2024
Via
Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
↗
May 08, 2024
Via
Benzinga
Expert Ratings For Apellis Pharmaceuticals
↗
April 15, 2024
Via
Benzinga
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
June 10, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
May 24, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today
↗
April 10, 2024
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
↗
March 29, 2024
Via
Benzinga
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
↗
March 27, 2024
Via
Benzinga
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
May 14, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
↗
May 07, 2024
APLS stock results show that Apellis Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Peering Into Apellis Pharmaceuticals's Recent Short Interest
↗
March 15, 2024
Via
Benzinga
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings)
↗
February 28, 2024
Via
Benzinga
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
May 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
April 26, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
April 23, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
The 5 Stocks Most Sold By Insiders This Year
April 16, 2024
Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices.
Via
MarketBeat
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
March 11, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Via
MarketBeat
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
February 28, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
